Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crowley

Showing results (171-180 of 178) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 178 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyAlberto S Pappo, Shreyaskumar R Patel, John Crowley, et al.
Blood|February 13, 2008
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupHeinz Ludwig, Brian G M Durie, Vanessa Bolejack, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 16, 2019
The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung CancerJohn G Edwards, Kari Chansky, Paul Van Schil, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Blood|November 16, 2006
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy, Fenghuang Zhan, Bart E Burington, et al.
The Lancet. Oncology|October 10, 2017
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialHussein A Tawbi, Melissa Burgess, Vanessa Bolejack, et al.
Plos Genetics|July 3, 2007
Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populationsEric Spierings, Matthijs Hendriks, Léna Absi, et al.
Cancer Cell|May 3, 2016
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 SignalingXing-Ding Zhang, Veerabhadran Baladandayuthapani, Heather Lin, et al.
Pageof 18

Showing results (171-180 of 178) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 178 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyAlberto S Pappo, Shreyaskumar R Patel, John Crowley, et al.
Blood|February 13, 2008
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupHeinz Ludwig, Brian G M Durie, Vanessa Bolejack, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 16, 2019
The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung CancerJohn G Edwards, Kari Chansky, Paul Van Schil, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Blood|November 16, 2006
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy, Fenghuang Zhan, Bart E Burington, et al.
The Lancet. Oncology|October 10, 2017
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialHussein A Tawbi, Melissa Burgess, Vanessa Bolejack, et al.
Plos Genetics|July 3, 2007
Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populationsEric Spierings, Matthijs Hendriks, Léna Absi, et al.
Cancer Cell|May 3, 2016
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 SignalingXing-Ding Zhang, Veerabhadran Baladandayuthapani, Heather Lin, et al.
Pageof 18